How we will treat chronic myeloid leukemia in 2016

Blood Reviews

Volumn 29, Issue 2, 2015, Pages 137-142

  Talati, Chetasi ^a   Ontiveros, Evelena P ^b   Griffiths, Elizabeth A ^b   Wang, Eunice S ^b   Wetzler, Meir ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chronic myeloid leukemia; Generic; Price of drugs; Tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; DASATINIB; GLUCOSE; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; BLEEDING; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CONGESTIVE CARDIOMYOPATHY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EFFUSION; EYE TOXICITY; FATIGUE; FLUID RETENTION; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; MYOSITIS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PULMONARY HYPERTENSION; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TELEMONITORING; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG RESISTANCE; ECONOMICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS;

EID: 84932620820     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.12.003     Document Type: Article

References (41)

1. Schwetz B.A. From the Food and Drug Administration. JAMA 2001, 286:35.
2. Kantarjian H.M., Shah N.P., Cortes J.E., Baccarani M., Agarwal M.B., Undurraga M.S., et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012, 119:1123-1129.
3. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
4. Radich J.P., Kopecky K.J., Appelbaum F.R., Kamel-Reid S., Stock W., Malnassy G., et al. A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012, 120:3898-3905.
5. Hehlmann R., Muller M.C., Lauseker M., Hanfstein B., Fabarius A., Schreiber A., et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014, 32:415-423.
6. Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
7. Sokal J.E., Cox E.B., Baccarani M., Tura S., Gomez G.A., Robertson J.E., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
8. Hasford J., Pfirrmann M., Hehlmann R., Allan N.C., Baccarani M., Kluin-Nelemans J.C., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850-858.
9. Hasford J., Baccarani M., Hoffmann V., Guilhot J., Saussele S., Rosti G., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011, 118:686-692.
10. Experts in Chronic Myeloid L The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121:4439-4442.
11. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
12. O'Brien S., Radich J.P., Abboud C.N., Akhtari M., Altman J.K., Berman E., et al. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw 2013, 11:1327-1340.
13. Vigil C.E., Griffiths E.A., Wang E.S., Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Rev 2011, 25:139-146.
14. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
15. Kaeda J., O'Shea D., Szydlo R.M., Olavarria E., Dazzi F., Marin D., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107:4171-4176.
16. Arpinati M., Tolomelli G., Bochicchio M.T., Castagnetti F., Amabile M., Bandini G., et al. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2013, 19:735-740.
17. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
18. Marin D., Ibrahim A.R., Lucas C., Gerrard G., Wang L., Szydlo R.M., et al. Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
19. Branford S., Yeung D.T., Parker W.T., Roberts N.D., Purins L., Braley J.A., et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014, 124:511-518.
20. Kantarjian H., O'Brien S., Jabbour E., Shan J., Ravandi F., Kadia T., et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 2011, 29:3173-3178.
21. Hochhaus A., Guilhot F., Al-Ali H.K., Rosti G., Nakaseko C., De Souza C., et al. Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly-diagnosed patients with chronic myeloid leukemia in chronic phase: Analysis of ENESTND 3-year data. Haematologica 2012, 97:237.
22. Hughes T.P., Hochhaus A., Kantarjian H.M., Cervantes F., Guilhot F., Niederwieser D., et al. Safety and efficacy of switching to nilotinib 400mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300mg twice daily. Haematologica 2014, 99:1204-1211.
23. Larson R.A., Hochhaus A., Hughes T.P., Clark R.E., Etienne G., Kim D.W., et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012, 26:2197-2203.
24. Jabbour E., Kantarjian H.M., Saglio G., Steegmann J.L., Shah N.P., Boque C., et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014, 123:494-500.
25. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
26. Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program 2011, 2011:128-135.
27. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
28. Santoleri F., Sorice P., Lasala R., Rizzo R.C., Costantini A. Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLoS One 2013, 8:e56813.
29. Holloway S., Lord K., Bethelmie-Bryan B., Shepard M.W., Neely J., McLemore M., et al. Managing chronic myeloid leukemia: a coordinated team care perspective. Clin Lymphoma Myeloma Leuk 2012, 12:88-93.
30. Kantarjian H.M., Cortes J.E., Kim D.W., Khoury H.J., Brummendorf T.H., Porkka K., et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014, 123:1309-1318.
31. Cortes J.E., Kim D.W., Pinilla-Ibarz J., le Coutre P., Paquette R., Chuah C., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
32. Zabriskie M.S., Eide C.A., Tantravahi S.K., Vellore N.A., Estrada J., Nicolini F.E., et al. BCR-ABL1 compound mutations combining Key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014, 26:428-442.
33. Miller G.D., Bruno B.J., Lim C.S. Resistant mutations in CML and Ph(+)ALL-role of ponatinib. Biologics 2014, 8:243-254.
34. Mahadeo K.M., Cole P.D. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS. Blood 2010, 115:3852.
35. Cortes J., Lipton J.H., Rea D., Digumarti R., Chuah C., Nanda N., et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012, 120:2573-2580.
36. Shah N.P. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005, 183-187.
37. Jain N., van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am 2011, 25:1025-1048.
38. Jabbour E., Cortes J., Kantarjian H.M., Giralt S., Jones D., Jones R., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006, 108:1421-1423.
39. Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
40. Ross D.M., Branford S., Seymour J.F., Schwarer A.P., Arthur C., Yeung D.T., et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013, 122:515-522.
41. Rousselot P., Charbonnier A., Cony-Makhoul P., Agape P., Nicolini F.E., Varet B., et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014, 32:424-430.